HER-2/neu expression in salivary duct carcinoma: An immunohistochemical and chromogenic in situ hybridization study

Applied Immunohistochemistry and Molecular Morphology

Volumn 16, Issue 1, 2008, Pages 54-58

  Johnson, Christopher J ^a   Barry, Michelle B ^b   Vasef, Mohammad A ^b   DeYoung, Barry R ^a,c  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c RCP   (United States)

Author keywords

CISH; HER 2 neu; Immunohistochemistry; Salivary duct carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORMALDEHYDE; PARAFFIN; TRASTUZUMAB;

ARTICLE; CLINICAL ARTICLE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SALIVARY GLAND CARCINOMA; TISSUE SECTION;

CARCINOMA, DUCTAL; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; RECEPTOR, ERBB-2; SALIVARY GLAND NEOPLASMS;

EID: 37549013275     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31802e91b2     Document Type: Article

References (39)

1. Lewis JE, McKinney BC, Weiland LH, et al. Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer. 1996;77:223-230.
2. Brandwein MS, Jagirdar J, Patil J, et al. Salivary gland carcinoma (cribriform salivary gland carcinoma of excretory ducts). A clinicopathologic and immunohistochemical study of 12 cases. Cancer. 1990;65:2307-2314.
3. Kleinsasser O, Klein HJ, Hubner G. Speichelgangcarcinoma. Ein den milchgangcarcinomen der brustdruse analoge gruppe von speicheldrusentumoren. ArchKlin Exp Ohren Nasen Kehlkopfheilkd. 1968;192:100-105.
4. Seifert G, Sobin LH. Histological Typing of Salivary Gland Tumours. World Health Organization International Histological Classification of Tumors. 2nd ed. New York, NY: Springer-Verlag; 1991.
5. Eriksen HE, Greisen O, Hasstrup N. Ductal carcinoma of the parotid gland. J Laryngol Otol. 1987;101:636-638.
6. Chen KTK, Hafez GR. Infiltrating salivary duct carcinoma. Arch Otolaryngol. 1981;107:37-39.
7. Barnes L, Rao U, Krause J, et al. Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol. 1994;78:64-73.
8. Wick MR, Ockner DM, Mills SE, et al. Homologous carcinoma of the breast, skin and salivary glands; a histologic and immunohistochemical comparison of ductal mammary carcinoma, ductal sweat gland carcinoma, and salivary duct carcinoma. Am J Clin Pathol. 1998;109:75-84.
9. Madrigal B, Garcia J, De Vicente JC. Salivary duct carcinoma: an unusual case of long-term evolution. Oral Surg Oral Med Oral Pathol. 1999;88:597-602.
10. Felix A, El-Naggar AK, Press MF, et al. Prognostic significance of biomarkers (c-erbB-2, P53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Path. 1996;27:561-566.
11. Barnes L, Rao U, Krause J, et al. Salivary duct carcinoma. Part II: immunohistochemical evaluation of 12 cases for estrogen and progesterone receptors, cathepson D and C-erbB-2 protein. Oral Surg Oral Med Oral Pathol. 1994;78:74-80.
12. Hellquist HB, Karlsson MG, Nilsson C. Salivary duct carcinoma - A highly aggressive salivary gland tumor with overexpression of c-erbB-2. J Pathol. 1994;172:35-44.
13. Martinex-Barba E, Cortes-Guardiola JA, Pinguela-Pura A, et al. Salivary duct carcinoma: clinicopathological and immunohistochemical studies. J Craniomaxillofac Surg. 1997;25:328-334.
14. Kamio N. Coexpression of p53 and c-erbB-2 proteins is associated with histologic type, tumour stage, and cell proliferation in malignant salivary gland tumours. Virchows Arch. 1996;428:75-83.
15. Skalova A, Starek I, Vanecek T, et al. Expression of HER-2/neu gene and protein in salivary duct carcinoma of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology. 2003;42:348-356.
16. Nagao T, Gaffey TA, Visscher DW, et al. Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance. Am J Surg Pathol. 2004;28:319-326.
17. Etges A, Pinto DS Jr, Kowalski LP. Salivary duct carcinoma: Immunohistochemical profile of an aggressive salivary gland tumor. J Clin Pathol. 2003;56:914-918.
18. Simpson RH, Prasad AR, Lewis JE, et al. Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases. Am J Surg Pathol. 2003;27:1020-1029.
19. Dagrada GP, Negri T, Tamborini E, et al. Expression of Her2-neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology. 2004;44:301-302.
20. Glisson B, Colevas AD, Haddad R, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Can Res. 2004;10:944-946.
21. Schechter AL, Hung MC, Vaidyanathan L, et al. The neu gene: an erb-B-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science. 1985;229:976-978.
22. Slamon DJ, Godolphin W, Jones LA, et al. Studies of Her-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
23. Gusterson BA, Gelber RD, Goldchirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol. 1992;10:1049-1056.
24. Slamon D, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
25. Press Mf, Pike MC, Chazin VR, et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantification by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993;53:4960-4970.
26. Nicholson BP. Ongoing and planned trials of hormonal therapy and trastuzumab. Semin Oncol. 2001;28:1-12.
27. Fornier M, Estava FJ, Seidman AD. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin Oncol. 2000;27:38-45.
28. Roche PC, Ingle JN. Increased Her2 with U.S. Food and Drug Administration-approved scoring system. J Clin Oncol. 1999;17:434.
29. Jacobs TW, Gown AM, Yaziji H, et al. Specificity of Hercep Test in determining Her-2/neu status of breast cancer using the United States Food and Drug Administration-approved scoring system. J Clin Oncol. 1999;17:1983-1987.
30. Deepali G, Middleton LP, Whitaker MJ, et al. Comparison of fluorescence and chromogenic in situ hybridization for detection of Her-2/neu oncogene in breast cancer. Am J Clin Pathol. 2003;119:381-387.
31. Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization. A practical alternative for fluorescence in situ hybridization to detect Her-2/neu oncogene amplification in archival breast cancer samples. Am J Path. 2000;157:1467-1472.
32. Kumamoto H, Sasano H, Taniguchi T, et al. Chromogenic in situ hybridization as analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy. Pathol Int. 2001;51:579-584.
33. Zhoa J, Wu R, Au A, et al. Determination of Her2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol. 2002;82:1007-1014.
34. Dandachi N, Dietze O, Hauser-Kronberger C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest. 2002;82:1007-1014.
35. Seifert G, Caselitz J. Epithelial salivary gland tumors: tumor markers. Prog Surg Pathol. 1989;9:157-187.
36. Kumar RV, Kini L, Bhargava AK, et al. Salivary duct carcinoma. J Surg Oncol. 1993;54:193-198.
37. Fan C, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma. An immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol. 2000;24:579-586.
38. Kapadia SB, Barnes L. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Mod Pathol. 1998;11:1033-1038.
39. Haddad R, Colevas A, Krane J, et al. Herceptin in patients with advanced or metatatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003;39:724-727.